Cannabinoid Encyclopedia

Safety words

What does Adverse event mean?

A safety observation reported in a source, with context about population and product. 1

Also called: adverse events, side effect, side effects, tolerability

Simple definition

Adverse event, in plain English

A safety observation reported in a source, with context about population and product. 1

Why it matters

How this word is used in cannabinoid research

This word helps describe a possible risk, side effect, or interaction. The dose, product, route, and person still matter.

How to read it

Read the definition beside the study details, including dose, route, product, population, and outcome.

Common questions

Questions people ask

What does Adverse event mean?

A safety observation reported in a source, with context about population and product.

Why does Adverse event matter?

This word helps describe a possible risk, side effect, or interaction. The dose, product, route, and person still matter.

Is Adverse event proof that a cannabinoid works?

No. A definition helps explain the language. The related research pages and their sources show what was actually studied.

Sources

Research connected to this term

Definitions explain the word. These links show research records currently connected with it.

  1. 1
    A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality preliminary human PubMed 37796540
  2. 2
    A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep preliminary human PubMed 39204082
  3. 3
    Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial preliminary human PubMed 41698831
  4. 4
    Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. insufficient PubMed 36206805
  5. 5
    Cannabidiol's impact on drug-metabolization. insufficient PubMed 37541924
  6. 6
    A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. insufficient PubMed 35156171
See all 323 connected research sources
  1. 1
    A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality preliminary human PubMed 37796540
  2. 2
    A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep preliminary human PubMed 39204082
  3. 3
    Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial preliminary human PubMed 41698831
  4. 4
    Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. insufficient PubMed 36206805
  5. 5
    Cannabidiol's impact on drug-metabolization. insufficient PubMed 37541924
  6. 6
    A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. insufficient PubMed 35156171
  7. 7
    Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. insufficient PubMed 33497784
  8. 8
    Cannabis and driving ability. insufficient PubMed 33839427
  9. 9
    Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review. insufficient PubMed 40172477
  10. 10
    Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. preliminary human PubMed 38797087
  11. 11
    Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. preliminary human PubMed 35617670
  12. 12
    Cannabis Therapeutics and the Future of Neurology. mechanistic or pharmacological PubMed 30405366
  13. 13
    Investigational cannabinoids in seizure disorders, what have we learned thus far? insufficient PubMed 29842819
  14. 14
    Cannabinoid Content in Cannabis Flowers and Homemade Cannabis-Based Products Used for Therapeutic Purposes in Argentina. preliminary human PubMed 33998894
  15. 15
    A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. mechanistic or pharmacological PubMed 30374683
  16. 16
    Memantine for autism spectrum disorder. insufficient PubMed 36006807
  17. 17
    Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. insufficient PubMed 39007525
  18. 18
    Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm. insufficient PubMed 39854828
  19. 19
    Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. insufficient PubMed 31288397
  20. 20
    Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs. insufficient PubMed 32918835
  21. 21
    Pharmacotherapies for cannabis use disorder. insufficient PubMed 41025421
  22. 22
    Mechanisms of cannabis impairment: Implications for modeling driving performance. insufficient PubMed 34634690
  23. 23
    Prescribing medicinal cannabis. insufficient PubMed 33093741
  24. 24
    Driving Impairment Cases Involving Etizolam and Flubromazolam. insufficient PubMed 32399568
  25. 25
    Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. mechanistic or pharmacological PubMed 27573936
  26. 26
    Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. insufficient PubMed 42339654
  27. 27
    Quality and safety of hemp meal as a protein supplement for nonlactating dairy cows. preliminary human PubMed 37641272
  28. 28
    Semiquantitative Screening of THC Analogues by Silica Gel TLC with an Ag(I) Retention Zone and Chromogenic Smartphone Detection. insufficient PubMed 36178203
  29. 29
    Plasma cannabinoid concentrations and transference during long-term industrial hemp administration in cattle. mechanistic or pharmacological PubMed 41358942
  30. 30
    Determination of Cannabinoids in Meat Products and Animal Feeds in Singapore Using Liquid Chromatography-Tandem Mass Spectrometry. preclinical PubMed 39200508
  31. 31
    Identification and Quantification of the Main Psychoactive Ingredients of Cannabis in Urine Using Excitation-Eemission Matrix Fluorescence Coupled with Parallel Factor Analysis. insufficient PubMed 37810707
  32. 32
    Ultrafast, Selective, and Highly Sensitive Nonchromatographic Analysis of Fourteen Cannabinoids in Cannabis Extracts, Δ8-Tetrahydrocannabinol Synthetic Mixtures, and Edibles by Cyclic Ion Mobility Spectrometry-Mass Spectrometry. insufficient PubMed 38862388
  33. 33
    Quality Control of Traditional Cannabis Tinctures: Pattern, Markers, and Stability. insufficient PubMed 28117322
  34. 34
    Pharmacologic treatment of fibromyalgia: an update. insufficient PubMed 41142233
  35. 35
    The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. insufficient PubMed 21845389
  36. 36
    Cannabis-based medicines for chronic neuropathic pain in adults. insufficient PubMed 41548880
  37. 37
    Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey. insufficient PubMed 40708053
  38. 38
    Adverse events associated with medical cannabis reported within a centralized call center. preliminary human PubMed 42158949
  39. 39
    Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. preclinical PubMed 35364618
  40. 40
    Preclinical safety and efficacy of cannabidivarin for early life seizures. preclinical PubMed 30633929
  41. 41
    Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. preclinical PubMed 26439367
  42. 42
    Self-reported adverse events associated with ∆8-Tetrahydrocannabinol (Delta-8-THC) Use. insufficient PubMed 37217977
  43. 43
    Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. insufficient PubMed 38868665
  44. 44
    Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. insufficient PubMed 39805119
  45. 45
    Prevalence of carboxy-Δ8-tetrahydrocannabiniol in antidoping samples. insufficient PubMed 38176407
  46. 46
    Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. insufficient PubMed 36742440
  47. 47
    Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report. preliminary human PubMed 36941718
  48. 48
    Using Large Language Models to Support Content Analysis: A Case Study of ChatGPT for Adverse Event Detection. preliminary human PubMed 38696245
  49. 49
    Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. mechanistic or pharmacological PubMed 39596290
  50. 50
    Cannabinoids in clinical practice. insufficient PubMed 11152013
  51. 51
    A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). preliminary human PubMed 37947792
  52. 52
    Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system. insufficient PubMed 40206058
  53. 53
    Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. mechanistic or pharmacological PubMed 42163693
  54. 54
    Safety study of cannabidiol products in healthy dogs. preliminary human PubMed 38496308
  55. 55
    Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. preliminary human PubMed 42057192
  56. 56
    Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. mechanistic or pharmacological PubMed 39004335
  57. 57
    Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. mechanistic or pharmacological PubMed 41822224
  58. 58
    The Potential of Cannabichromene (CBC) as a Therapeutic Agent. insufficient PubMed 38777605
  59. 59
    Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. insufficient PubMed 40872492
  60. 60
    Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. insufficient PubMed 37630401
  61. 61
    The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. preliminary human PubMed 37162192
  62. 62
    A systematic review of analytical methodologies capable of analysing phytocannabinoids in cosmetics. insufficient PubMed 38229238
  63. 63
    Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. preclinical PubMed 40580638
  64. 64
    Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. preclinical PubMed 37721989
  65. 65
    CBD, a precursor of THC in e-cigarettes. insufficient PubMed 33903673
  66. 66
    The antinociceptive activity and mechanism of action of cannabigerol. preclinical PubMed 36916438
  67. 67
    Update on Cannabidiol in Drug-Resistant Epilepsy. insufficient PubMed 39585547
  68. 68
    A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. insufficient PubMed 31802404
  69. 69
    Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. insufficient PubMed 33667843
  70. 70
    Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program. insufficient PubMed 37593907
  71. 71
    Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. insufficient PubMed 37648266
  72. 72
    Cannabis Use and the Risk for Psychosis and Affective Disorders. insufficient PubMed 31647377
  73. 73
    Relationships between cannabis use and mental disorders: assessing the coherence of evidence from studies with different methodologies. insufficient PubMed 42309106
  74. 74
    Cannabis and psychiatric disorders. insufficient PubMed 20562767
  75. 75
    The contribution of addictovigilance data to the French medical cannabis experimentation. preliminary human PubMed 39547825
  76. 76
    Role of cannabis in cardiovascular disorders. insufficient PubMed 28840009
  77. 77
    Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. preclinical PubMed 36603937
  78. 78
    A Phase-2 Open-Label Trial of Cannabidiol to Treat Core and Associated Symptoms of Autism in Children and Adolescents Without Intellectual Disability. preliminary human PubMed 42204954
  79. 79
    Clinical management of cannabis withdrawal. insufficient PubMed 34791767
  80. 80
    Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. insufficient PubMed 35510826
  81. 81
    The differential effects of medicinal cannabis on mental health: A systematic review. insufficient PubMed 40186931
  82. 82
    Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples. insufficient PubMed 38562466
  83. 83
    Cannabinoids and monoaminergic system: implications for learning and memory. insufficient PubMed 39206116
  84. 84
    Adverse Effects of Recreational and Medical Cannabis. preliminary human PubMed 33897066
  85. 85
    Prenatal cannabinoid exposure and altered neurotransmission. insufficient PubMed 30771373
  86. 86
    Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. insufficient PubMed 26858214
  87. 87
    Endocannabinoid signaling and long-term synaptic plasticity. insufficient PubMed 19575681
  88. 88
    Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies. insufficient PubMed 42076122
  89. 89
    Hexahydrocannabinol-induced rhabdomyolysis and acute kidney injury: a case report combining comprehensive toxicokinetic and metabolomic investigations. mechanistic or pharmacological PubMed 42106886
  90. 90
    [Not all drugs are the same]. insufficient PubMed 23974649
  91. 91
    Brands of Intoxicating Cannabis Products in Vape Shops: United States, 2023. insufficient PubMed 41324909
  92. 92
    Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? insufficient PubMed 17005273
  93. 93
    Cardiovascular consequences of marijuana use. insufficient PubMed 12412838
  94. 94
    Acute Effects of Cannabis Inhalation on Arterial Stiffness, Vascular Endothelial Function, and Cardiac Function. insufficient PubMed 39575727
  95. 95
    Cannabis use and acute coronary syndrome. insufficient PubMed 30964363
  96. 96
    Endocannabinoids, blood pressure and the human heart. insufficient PubMed 18426501
  97. 97
    Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. preliminary human PubMed 26724101
  98. 98
    Cannabinoid treatment for autism: a proof-of-concept randomized trial. mechanistic or pharmacological PubMed 33536055
  99. 99
    Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. preliminary human PubMed 29768152
  100. 100
    Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. preliminary human PubMed 28538134
  101. 101
    A new HPLC method with multiple detection systems for impurity analysis and discrimination of natural versus synthetic cannabidiol. insufficient PubMed 38940871
  102. 102
    Statewide Variation in Cannabinoid Regulations. insufficient PubMed 36848540
  103. 103
    Cannabis Contaminants Limit Pharmacological Use of Cannabidiol. insufficient PubMed 33013414
  104. 104
    Pesticides and trace elements in cannabis: Analytical and environmental challenges and opportunities. insufficient PubMed 31471034
  105. 105
    Cautious Hope for Cannabidiol (CBD) in Rheumatology Care. insufficient PubMed 32144889
  106. 106
    Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. insufficient PubMed 27683558
  107. 107
    Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products. insufficient PubMed 35987236
  108. 108
    Cannabidiol Gummy Products: LC-MS/MS Assessment of Cannabinoid Concentrations. insufficient PubMed 40454463
  109. 109
    Acid-Catalyzed Conversion of Cannabidiol to Tetrahydrocannabinols: En Route to Demystifying Manufacturing Processes and Controlling the Reaction Outcomes. insufficient PubMed 40250991
  110. 110
    Potency Analysis of Medical Marijuana Products from New York State. preliminary human PubMed 31559335
  111. 111
    Delta-8 tetrahydrocannabinol: a scoping review and commentary. insufficient PubMed 36710464
  112. 112
    The potential role of cannabinoids in dermatology. insufficient PubMed 31599175
  113. 113
    Cannabis and the skin. insufficient PubMed 34785006
  114. 114
    Cannabinoids in dermatology: a scoping review. preliminary human PubMed 30142706
  115. 115
    Cannabinoids and Their Receptors in Skin Diseases. insufficient PubMed 38003712
  116. 116
    Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science. insufficient PubMed 41008526
  117. 117
    Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids. insufficient PubMed 33851375
  118. 118
    Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors. insufficient PubMed 38904694
  119. 119
    Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. insufficient PubMed 33909195
  120. 120
    The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. insufficient PubMed 30138623
  121. 121
    Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations. insufficient PubMed 36439142
  122. 122
    The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. insufficient PubMed 19608284
  123. 123
    Modulators of the endocannabinoid system influence skin barrier repair, epidermal proliferation, differentiation and inflammation in a mouse model. mechanistic or pharmacological PubMed 31350927
  124. 124
    Delta-8 tetrahydrocannabinol, delta-10 tetrahydrocannabinol, and tetrahydrocannabinol-O acetate exposures reported to America's Poison Centers. insufficient PubMed 38686923
  125. 125
    Using Transformer-Based Topic Modeling to Examine Discussions of Delta-8 Tetrahydrocannabinol: Content Analysis. preliminary human PubMed 38127427
  126. 126
    Derivation of a health-based guidance value for Δ8-tetrahydrocannabinol (Δ8-THC) and its occurrence in food. preliminary human PubMed 41262681
  127. 127
    Delta-8 THC Retail Availability, Price, and Minimum Purchase Age. insufficient PubMed 36342930
  128. 128
    Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. preclinical PubMed 40643195
  129. 129
    [Not Available]. preliminary human PubMed 39323250
  130. 130
    A Survey Study of Individuals Using Hexahydrocannabinol Cannabis Products: Use Patterns and Perceived Effects. insufficient PubMed 37934167
  131. 131
    Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice. preclinical PubMed 40176500
  132. 132
    The Psychiatric Consequences of Cannabinoids. insufficient PubMed 29678279
  133. 133
    Pharmacotherapies for cannabis dependence. insufficient PubMed 30687936
  134. 134
    Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. insufficient PubMed 32271390
  135. 135
    The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. insufficient PubMed 41856154
  136. 136
    Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. insufficient PubMed 38427284
  137. 137
    Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. mechanistic or pharmacological PubMed 29540584
  138. 138
    Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. insufficient PubMed 40072476
  139. 139
    Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. preliminary human PubMed 39980821
  140. 140
    Examining the hepatotoxic potential of cannabidiol, cannabidiol-containing hemp extract, and cannabinol at consumer-relevant exposure concentrations in primary human hepatocytes. insufficient PubMed 38924151
  141. 141
    [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences]. insufficient PubMed 27428345
  142. 142
    Review of NIOSH Cannabis-Related Health Hazard Evaluations and Research. insufficient PubMed 32053725
  143. 143
    Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. insufficient PubMed 36228902
  144. 144
    Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. insufficient PubMed 39598860
  145. 145
    Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol. mechanistic or pharmacological PubMed 36796712
  146. 146
    Identification of Cannabigerol-Derived Dual CB2 Receptor Agonists and TRPM8 Antagonists with Anti-Inflammatory and Analgesic Activities. mechanistic or pharmacological PubMed 40540228
  147. 147
    Cannabigerol Mitigates Haloperidol-Induced Vacuous Chewing Movements in Mice. insufficient PubMed 39699828
  148. 148
    Cannabigerol does not affect contextual fear memory in mice but modulates nociception in a sex-dependent manner. preclinical PubMed 40523564
  149. 149
    Non-psychotropic cannabinoids as inhibitors of TET1 protein. insufficient PubMed 35462234
  150. 150
    Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, and In-vivo Analysis. insufficient PubMed 40326034
  151. 151
    Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. insufficient PubMed 33562819
  152. 152
    Could cannabigerol protect against neuroinflammation? Insights from an in vitro microglial study. mechanistic or pharmacological PubMed 41548647
  153. 153
    Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? insufficient PubMed 37414155
  154. 154
    The impact of cannabigerol exposure on human endometrial stromal cells decidualization. mechanistic or pharmacological PubMed 42107483
  155. 155
    The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling. insufficient PubMed 36497400
  156. 156
    Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects. insufficient PubMed 42352060
  157. 157
    Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. insufficient PubMed 32628766
  158. 158
    Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. mechanistic or pharmacological PubMed 36272108
  159. 159
    Therapeutic potential of phytocannabinoids in depression and cognitive dysfunction: Evidence from preclinical models. mechanistic or pharmacological PubMed 41934896
  160. 160
    Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. mechanistic or pharmacological PubMed 35246858
  161. 161
    Cannabis Vaping: Existing and Emerging Modalities, Chemistry, and Pulmonary Toxicology. insufficient PubMed 34622654
  162. 162
    Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. mechanistic or pharmacological PubMed 33134364
  163. 163
    Pre-puberty cannabichromene exposure modulates reproductive function via alteration of spermatogenesis, steroidogenesis, and eNOS pathway metabolites. insufficient PubMed 37396845
  164. 164
    Genotoxicity of selected cannabinoids in human lymphoblastoid TK6 cells. insufficient PubMed 39172143
  165. 165
    Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. mechanistic or pharmacological PubMed 20619971
  166. 166
    Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots. mechanistic or pharmacological PubMed 41668212
  167. 167
    Development and validation of a fit-for-purpose UHPLC-ESI-MS/MS method for the quantitation of cannabinoids in different matrices. insufficient PubMed 36854205
  168. 168
    The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management. insufficient PubMed 40270953
  169. 169
    CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant). insufficient PubMed 21740450
  170. 170
    SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity. mechanistic or pharmacological PubMed 42196303
  171. 171
    A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. preliminary human PubMed 37721990
  172. 172
    Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption. mechanistic or pharmacological PubMed 41947574
  173. 173
    Effect of cannabidiol, cannabinol and tetrahydrocannabivarin in managing inflammatory pain. preclinical PubMed 42151379
  174. 174
    Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing. insufficient PubMed 37697897
  175. 175
    Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies. insufficient PubMed 35799289
  176. 176
    Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers. insufficient PubMed 25542687
  177. 177
    The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. mechanistic or pharmacological PubMed 26577065
  178. 178
    Hair Regrowth with Novel Hemp Extract: A Case Series. mechanistic or pharmacological PubMed 37305187
  179. 179
    Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products. insufficient PubMed 40131178
  180. 180
    Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. insufficient PubMed 35303507
  181. 181
    The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. mechanistic or pharmacological PubMed 23712280
  182. 182
    Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. insufficient PubMed 31549358
  183. 183
    Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies. insufficient PubMed 36280497
  184. 184
    Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath. insufficient PubMed 35585089
  185. 185
    Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. insufficient PubMed 23894589
  186. 186
    Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region. mechanistic or pharmacological PubMed 38750093
  187. 187
    Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. insufficient PubMed 36150527
  188. 188
    Metabolism of endocannabinoids. insufficient PubMed 27516570
  189. 189
    Anandamide uptake explained? insufficient PubMed 22297258
  190. 190
    Anandamide receptors. insufficient PubMed 12052051
  191. 191
    The major endocannabinoid anandamide (AEA) induces apoptosis of human granulosa cells. mechanistic or pharmacological PubMed 34126378
  192. 192
    Endocannabinoid metabolism by cytochrome P450 monooxygenases. insufficient PubMed 25461979
  193. 193
    Endocannabinoids and pregnancy. insufficient PubMed 20302856
  194. 194
    Anandamide and its metabolites: what are their roles in the kidney? insufficient PubMed 27100705
  195. 195
    Endocannabinoids. mechanistic or pharmacological PubMed 35038882
  196. 196
    Cannabinoid CB1 receptors regulate salivation. mechanistic or pharmacological PubMed 35986066
  197. 197
    Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. mechanistic or pharmacological PubMed 11470906
  198. 198
    Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors. insufficient PubMed 32867595
  199. 199
    Druggable Targets in Endocannabinoid Signaling. insufficient PubMed 32894511
  200. 200
    Chemical probes of endocannabinoid metabolism. insufficient PubMed 23512546
  201. 201
    Amygdala FAAH and anandamide: mediating protection and recovery from stress. insufficient PubMed 24325918
  202. 202
    The Endocannabinoid System and its Modulation by Phytocannabinoids. insufficient PubMed 26271952
  203. 203
    The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. insufficient PubMed 21418147
  204. 204
    Cannabinergic ligands. insufficient PubMed 12505686
  205. 205
    Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. insufficient PubMed 16678907
  206. 206
    Endocannabinoid overload. insufficient PubMed 20952498
  207. 207
    Endocannabinoid hydrolases. insufficient PubMed 12432941
  208. 208
    Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. mechanistic or pharmacological PubMed 39612328
  209. 209
    Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. mechanistic or pharmacological PubMed 24768821
  210. 210
    Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. insufficient PubMed 36966972
  211. 211
    2-Arachidonoylglycerol-mediated endocannabinoid signaling modulates mechanical hypersensitivity associated with alcohol withdrawal in mice. mechanistic or pharmacological PubMed 36125319
  212. 212
    The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. mechanistic or pharmacological PubMed 33450278
  213. 213
    Augmentation of 2-arachidonoylglycerol signaling in astrocytes maintains synaptic functionality by regulation of miRNA-30b. mechanistic or pharmacological PubMed 36481187
  214. 214
    Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. insufficient PubMed 24676249
  215. 215
    A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence. preclinical PubMed 38052772
  216. 216
    Endocannabinoids and nutrition. insufficient PubMed 18426507
  217. 217
    N-acylethanolamines, anandamide and food intake. insufficient PubMed 19413995
  218. 218
    Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. insufficient PubMed 19285259
  219. 219
    Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. insufficient PubMed 30537148
  220. 220
    A fatty gut feeling. insufficient PubMed 23567058
  221. 221
    Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. mechanistic or pharmacological PubMed 17449181
  222. 222
    Regulation of food intake by oleoylethanolamide. insufficient PubMed 15770421
  223. 223
    The endocannabinoid and paracannabinoid systems in natural reward processes: possible pharmacological targets? insufficient PubMed 40274041
  224. 224
    Brain molecules and appetite: the case of oleoylethanolamide. insufficient PubMed 23464987
  225. 225
    The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice. mechanistic or pharmacological PubMed 29936173
  226. 226
    GPR119 Is a Potent Regulator of Human Sebocyte Biology. mechanistic or pharmacological PubMed 32142797
  227. 227
    Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy. mechanistic or pharmacological PubMed 30702457
  228. 228
    Regulation of Cholesterol and Triglyceride Metabolism by Fatty acid Ethanolamides. insufficient PubMed 42068417
  229. 229
    Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial. insufficient PubMed 31132422
  230. 230
    Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice. mechanistic or pharmacological PubMed 35176443
  231. 231
    Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain. insufficient PubMed 39714723
  232. 232
    The search for the palmitoylethanolamide receptor. insufficient PubMed 15963531
  233. 233
    Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation. mechanistic or pharmacological PubMed 40563990
  234. 234
    Probiotics and palmitoylethanolamide (PEA) for osteoarthritic pain: individual effects in a multiple baseline design study. mechanistic or pharmacological PubMed 41709243
  235. 235
    Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases. insufficient PubMed 28215162
  236. 236
    Cannabimimetic fatty acid derivatives in cancer and inflammation. insufficient PubMed 10785541
  237. 237
    Protective effect of palmitoylethanolamide in a rat model of cystitis. mechanistic or pharmacological PubMed 25463999
  238. 238
    Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence. insufficient PubMed 33919499
  239. 239
    Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). insufficient PubMed 24602801
  240. 240
    Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. insufficient PubMed 22697514
  241. 241
    Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. mechanistic or pharmacological PubMed 27720681
  242. 242
    Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. mechanistic or pharmacological PubMed 28336953
  243. 243
    Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. insufficient PubMed 11945157
  244. 244
    Oleamide: a member of the endocannabinoid family? insufficient PubMed 14691053
  245. 245
    Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? insufficient PubMed 17445087
  246. 246
    The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? insufficient PubMed 10469890
  247. 247
    The role of the CB1 receptor in the regulation of sleep. insufficient PubMed 18514375
  248. 248
    The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. mechanistic or pharmacological PubMed 9344854
  249. 249
    The enzymatic inactivation of the fatty acid amide class of signaling lipids. insufficient PubMed 12505696
  250. 250
    Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. insufficient PubMed 10197045
  251. 251
    Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. mechanistic or pharmacological PubMed 10221757
  252. 252
    Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. mechanistic or pharmacological PubMed 8900284
  253. 253
    The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist. mechanistic or pharmacological PubMed 10574567
  254. 254
    N-Arachidonoyl Dopamine: A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities. insufficient PubMed 29082315
  255. 255
    TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat. mechanistic or pharmacological PubMed 15245490
  256. 256
    Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. mechanistic or pharmacological PubMed 17459108
  257. 257
    The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. mechanistic or pharmacological PubMed 24644287
  258. 258
    Endovanilloids are potential activators of the trigeminovascular nocisensor complex. mechanistic or pharmacological PubMed 27189587
  259. 259
    Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population. mechanistic or pharmacological PubMed 20354008
  260. 260
    Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. mechanistic or pharmacological PubMed 15289293
  261. 261
    Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. mechanistic or pharmacological PubMed 15006899
  262. 262
    A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells. mechanistic or pharmacological PubMed 25995819
  263. 263
    N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1. mechanistic or pharmacological PubMed 28701511
  264. 264
    N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. mechanistic or pharmacological PubMed 16760924
  265. 265
    Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel. mechanistic or pharmacological PubMed 33568652
  266. 266
    Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor. mechanistic or pharmacological PubMed 17984664
  267. 267
    Endocannabinoids and Their Pharmacological Actions. insufficient PubMed 26408156
  268. 268
    2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. mechanistic or pharmacological PubMed 11259648
  269. 269
    The cannabinoid receptors. insufficient PubMed 12432948
  270. 270
    Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. mechanistic or pharmacological PubMed 17698254
  271. 271
    Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. mechanistic or pharmacological PubMed 16639008
  272. 272
    Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. mechanistic or pharmacological PubMed 12787057
  273. 273
    The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. mechanistic or pharmacological PubMed 15901805
  274. 274
    Activation of CB1R alleviates central sensitization by regulating HCN2-pNR2B signaling in a chronic migraine rat model. mechanistic or pharmacological PubMed 37085778
  275. 275
    Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor. mechanistic or pharmacological PubMed 15148262
  276. 276
    Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats. mechanistic or pharmacological PubMed 22309979
  277. 277
    Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. preclinical PubMed 15763177
  278. 278
    Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. mechanistic or pharmacological PubMed 12356827
  279. 279
    GPR55: a new member of the cannabinoid receptor clan? insufficient PubMed 17876300
  280. 280
    Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. mechanistic or pharmacological PubMed 18806815
  281. 281
    Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. mechanistic or pharmacological PubMed 12023533
  282. 282
    The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. mechanistic or pharmacological PubMed 22454039
  283. 283
    Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria. mechanistic or pharmacological PubMed 32696508
  284. 284
    Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. mechanistic or pharmacological PubMed 15233865
  285. 285
    Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B. mechanistic or pharmacological PubMed 29958841
  286. 286
    Mechanism of platelet activation induced by endocannabinoids in blood and plasma. mechanistic or pharmacological PubMed 23789792
  287. 287
    (Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells. mechanistic or pharmacological PubMed 19255745
  288. 288
    Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. insufficient PubMed 22959887
  289. 289
    N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. mechanistic or pharmacological PubMed 27809877
  290. 290
    N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation. mechanistic or pharmacological PubMed 23570577
  291. 291
    Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function. mechanistic or pharmacological PubMed 27759003
  292. 292
    A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. insufficient PubMed 21810478
  293. 293
    Classical endocannabinoid-like compounds and their regulation by nutrients. insufficient PubMed 24677570
  294. 294
    Oral ibuprofen differentially affects plasma and sweat lipid mediator profiles in healthy adult males. preliminary human PubMed 29778785
  295. 295
    Role of anorectic N-acylethanolamines in intestinal physiology and satiety control with respect to dietary fat. insufficient PubMed 24681513
  296. 296
    Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder. preliminary human PubMed 37298321
  297. 297
    Dietary oleic acid contributes to the regulation of food intake through the synthesis of intestinal oleoylethanolamide. preclinical PubMed 36733808
  298. 298
    The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study. mechanistic or pharmacological PubMed 35203453
  299. 299
    Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. preclinical PubMed 18316044
  300. 300
    Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine. mechanistic or pharmacological PubMed 21573043
  301. 301
    Gene Expression of Endocannabinoid System Components in Skeletal Muscle and Adipose Tissue of South Asians and White Caucasians with Overweight. insufficient PubMed 30070030
  302. 302
    Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. insufficient PubMed 11463796
  303. 303
    Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome. preclinical PubMed 36316276
  304. 304
    Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease. mechanistic or pharmacological PubMed 26707833
  305. 305
    Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. mechanistic or pharmacological PubMed 16081411
  306. 306
    Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. mechanistic or pharmacological PubMed 17574742
  307. 307
    Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. insufficient PubMed 20353771
  308. 308
    Stearoylethanolamide interferes with retrograde endocannabinoid signalling and supports the blood-brain barrier integrity under acute systemic inflammation. preclinical PubMed 31881191
  309. 309
    Roles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury. insufficient PubMed 24874648
  310. 310
    Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. mechanistic or pharmacological PubMed 12010121
  311. 311
    High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women. mechanistic or pharmacological PubMed 22125609
  312. 312
    Palmitoylethanolamide and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. mechanistic or pharmacological PubMed 23707281
  313. 313
    Serum levels of endocannabinoids and related lipids in painful vs painless diabetic neuropathy: results from the Pain in Neuropathy Study. preliminary human PubMed 37578507
  314. 314
    High levels of endogenous lipid mediators (N-acylethanolamines) in women with chronic widespread pain during acute tissue trauma. mechanistic or pharmacological PubMed 27531672
  315. 315
    N-Stearoylethanolamine Exerts Cardioprotective Effects in Old Rats. preclinical PubMed 38279735
  316. 316
    Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and Quantification. insufficient PubMed 26839710
  317. 317
    [Effects of N-stearoylethanolamine on the emotionality and learning ability of rats]. preclinical PubMed 25566671
  318. 318
    Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. insufficient PubMed 23813098
  319. 319
    [Immunosuppressive characteristics of N-stearoylethanolamine a stable compound with cannabimimetic activity]. preclinical PubMed 18710028
  320. 320
    [Anti-inflammatory effect of N-stearoylethanolamine in experimental burn injury in rats]. preclinical PubMed 19873884
  321. 321
    Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. mechanistic or pharmacological PubMed 16154384
  322. 322
    Exploring the Utility of Hair Endocannabinoids for Monitoring Homeostasis in Bonobos. preclinical PubMed 33434116
  323. 323
    Cannabinoids and Sleep/Wake Control. insufficient PubMed 33537938